Clinical Trials
124 trialsMMRC Horizon One: RRMM (MMRC-099)
Multiple Myeloma Research Consortium
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
M.D. Anderson Cancer Center
18F-Fluciclovine PET/CT in Multiple Myeloma
National Institutes of Health Clinical Center (CC)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
HALTAging-1
University of Nebraska
TAPUR
American Society of Clinical Oncology
IMPACT
University of Utah
CM336-RI
Institute of Hematology & Blood Diseases Hospital, China
MASTER-2
University of Alabama at Birmingham
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
National Cancer Institute (NCI)
ROTATE
Yale University
MonumenTAL-1
Janssen Research & Development, LLC
Talisman
Janssen Research & Development, LLC
CARTITUDE-10
Janssen Research & Development, LLC
TRIlogy-3
Janssen Research & Development, LLC
MoTD
University of Birmingham
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
City of Hope Medical Center
EMBRACE
Ontario Clinical Oncology Group (OCOG)
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
FASTER
SCRI Development Innovations, LLC
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
European Myeloma Network B.V.
CAR T-cell Therapy in Patients With Renal Dysfunction
Northside Hospital, Inc.
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Emory University
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
European Myeloma Network B.V.
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
M.D. Anderson Cancer Center
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Washington University School of Medicine
LINKER-MGUS1
Regeneron Pharmaceuticals
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
The First Hospital of Jilin University
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Mayo Clinic
CAPTUR
Canadian Cancer Trials Group
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
Chinese PLA General Hospital
BOREALIS
Canadian Myeloma Research Group
Elranatamab in R/R Multiple Myeloma
Massachusetts General Hospital
ELISA in Relapsed/Refractory MM
Massachusetts General Hospital
MOMENTUM
C4 Therapeutics, Inc.
Iber-KDd
University of Miami
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
Memorial Sloan Kettering Cancer Center
A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Memorial Sloan Kettering Cancer Center
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
HEME-18
University of Illinois at Chicago
SELVEDge
University of Miami
REVIVE
University of Miami